Jounce Therapeutics, Inc. (JNCE)

NASDAQ: JNCE · IEX Real-Time Price · USD
1.85
+0.01 (0.54%)
At close: Mar 29, 2023, 4:00 PM
1.86
+0.01 (0.54%)
Pre-market: Mar 30, 2023, 5:17 AM EDT
0.54%
Market Cap 96.46M
Revenue (ttm) 82.00M
Net Income (ttm) -50.92M
Shares Out 52.14M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE 19.46
Dividend n/a
Ex-Dividend Date n/a
Volume 3,284,590
Open 1.84
Previous Close 1.84
Day's Range 1.84 - 1.86
52-Week Range 0.58 - 7.94
Beta 0.63
Analysts Buy
Price Target 3.40 (+83.78%)
Earnings Date May 3, 2023

About JNCE

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2017
Employees 137
Stock Exchange NASDAQ
Ticker Symbol JNCE
Full Company Profile

Financial Performance

In 2022, JNCE's revenue was $82.00 million, an increase of 204.75% compared to the previous year's $26.91 million. Losses were -$50.92 million, -43.97% less than in 2021.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 83.78% from the latest price.

Price Target
$3.4
(83.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

1 day ago - Zacks Investment Research

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash ...

2 days ago - Business Wire

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

2 days ago - GlobeNewsWire

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pre...

1 week ago - GlobeNewsWire

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

1 week ago - Zacks Investment Research

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

Jounce Therapeutics (NASDAQ: JNCE) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences. That acquisition offer has Concentra Biosciences seeki...

2 weeks ago - InvestorPlace

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

2 weeks ago - GlobeNewsWire

Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account

Shares of Jounce Therapeutics Inc. JNCE, -6.09% bounced 6.6% in premarket trading Monday, after the immunotherapy company said only about $2.6 million, or 1.4% of its total cash and cash equivalents w...

Other symbols: SIVB
2 weeks ago - Market Watch

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Jounce Therapeutics, Inc. - JNCE

NEW YORK , Feb. 27, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm r...

1 month ago - PRNewsWire

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Jounce Therape...

1 month ago - Business Wire

Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?

Jounce Therapeutics (NASDAQ: JNCE) stock is on the rise Thursday after the company revealed merger plans with Redx Pharma . Jounce Therapeutics and Redx Pharma will undergo a merger with an all-stock...

1 month ago - InvestorPlace

JNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Jounce Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Redx Pharma is fair to Jounce shareholders...

1 month ago - Business Wire

Redx and Jounce Announce Recommended Business Combination

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease

1 month ago - GlobeNewsWire

Jounce Therapeutics Announces Restructuring

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

1 month ago - GlobeNewsWire

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Other symbols: GILD
3 months ago - Zacks Investment Research

Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?

Jounce Therapeutics (NASDAQ: JNCE) stock jumped after it sold rights to a cancer drug to Gilead Sciences (NASDAQ: GILD). Shares were trading as high as $1.30 in the pre-market, after closing under 7...

3 months ago - InvestorPlace

Gilead buys out rights to cancer therapy from Jounce for $67 mln

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

Other symbols: GILD
3 months ago - Reuters

Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug

Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, +0.31% would completely acquire rights to an...

Other symbols: GILD
3 months ago - Market Watch

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Oblig...

3 months ago - GlobeNewsWire

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (forme...

Other symbols: GILD
3 months ago - Business Wire

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -

3 months ago - GlobeNewsWire

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -

4 months ago - GlobeNewsWire

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

5 months ago - GlobeNewsWire

Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

5 months ago - GlobeNewsWire